PERCF (Percheron Therapeutics) Moat Score: 2/10 (As of Jun. 25, 2026)


What is Percheron Therapeutics Moat Score?

Percheron Therapeutics PERCF -42.86% Moat Score is 2 as of Jun. 25, 2026. The stock has 2 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Percheron Therapeutics ranks better than 81.7% on this metric.

Percheron Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Percheron Therapeutics has No Moat: Percheron Therapeutics has no discernible moat, operating in a competitive biotech industry with limited intellectual property and no significant regulatory barriers or brand strength to provide a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Percheron Therapeutics might have No Moat - Very weak/transient advantages.

Percheron Therapeutics  (OTCPK:PERCF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Percheron Therapeutics Moat Score Related Terms

PERCF vs ZTS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Percheron Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Percheron Therapeutics (PERCF) has a Moat Score of 2 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Percheron Therapeutics ranks #189 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Percheron Therapeutics' Moat Score too high?
Percheron Therapeutics' current Moat Score is 2. Based on the distribution chart, Percheron Therapeutics ranks #189 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Percheron Therapeutics' Moat Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #189 out of 1033 companies for Moat Score. This places Percheron Therapeutics in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Percheron Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Moat Score of 2. The current Moat Score is 2. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Moat Score is 2 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Percheron Therapeutics Business Description

Other Exchanges AWY0:GermanyPER:Australia
Address 35 Collins Street, Level 30, Collins Place, Melbourne, VIC, AUS, 3000
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.